SCHEMBL14596178

SCHEMBL14596178

CN(C)CCCNc1nc(CN(C)S(=O)(=O)c2ccc(Oc3ccccc3)cc2)nc2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 4/20 0.53
POLB P06746 3/20 0.53
RXFP1 Q9HBX9 1/20 0.53
FLT3 P36888 6/20 0.52
ALDH1A1 P00352 1/20 0.49
MAPK1 P28482 1/20 0.49
SCN9A Q15858 1/20 0.46
TOP2A P11388 2/20 0.46
KMT2A Q03164 2/20 0.45
NPC1 O15118 1/20 0.45
SLC2A1 P11166 1/20 0.45
APOBEC3A P31941 1/20 0.45
RAB9A P51151 1/20 0.45
APOBEC3G Q9HC16 1/20 0.45
CACNA1B Q00975 1/20 0.45
TERT O14746 2/20 0.44
MERTK Q12866 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14596154 0.93 RAD52 (0.62) RAD52POLBRXFP1FLT3ALDH1A1
SCHEMBL14596174 0.89 ALDH1A1 (0.57) RAD52POLBRXFP1FLT3ALDH1A1
SCHEMBL14596176 0.89 FLT3 (0.65) RAD52POLBRXFP1FLT3ALDH1A1
SCHEMBL14596148 0.89 RAD52 (0.60) RAD52POLBRXFP1FLT3ALDH1A1
SCHEMBL14596150 0.89 FLT3 (0.57) RAD52POLBRXFP1FLT3ALDH1A1
SCHEMBL14596177 0.89 FLT3 (0.54) RAD52POLBRXFP1FLT3ALDH1A1
SCHEMBL14596152 0.89 FLT3 (0.54) RAD52POLBRXFP1FLT3ALDH1A1
SCHEMBL14596153 0.88 RAD52 (0.55) RAD52POLBRXFP1FLT3ALDH1A1
SCHEMBL14596163 0.88 FLT3 (0.53) RAD52POLBRXFP1FLT3ALDH1A1
SCHEMBL14596166 0.85 FLT3 (0.54) RAD52POLBRXFP1FLT3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-01-18 US disclosed
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment TP53, TP53BP1, ACIN1 RAD52 954/4885POLB 800/4885RXFP1 1985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.